REAL-WORLD COMPARISON OF HEALTHCARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. LIRAGLUTIDE IN THE UNITED STATES

被引：0
|
作者：
Mody, R. [1 ]
Huang, Q. [2 ]
Yu, M. [3 ]
Patel, H. [1 ]
Zhao, R. [2 ]
Grabner, M. [2 ]
Lando, Fernandez L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Eli Lilly & Co, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.520
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB89
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [21] Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
    Mody, Reema
    Grabner, Michael
    Yu, Maria
    Turner, Ralph
    Kwan, Anita Y. M.
    York, Whitney
    Lando, Laura Fernandez
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 995 - 1003
  • [22] Real-World Glycemic Control after Six Months of Treatment with Exenatide Once Weekly vs. Dulaglutide or Albiglutide in Patients with Type 2 Diabetes
    Unni, Sudhir
    Schauerhamer, Marisa B.
    Ma, Junjie
    Wittbrodt, Eric
    Hurd, Jeff
    Ye, Xiangyang
    Mcadam-Marx, Carrie
    DIABETES, 2017, 66 : A308 - A308
  • [23] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Garcia-Perez, Luis-Emilio
    Boye, Kristina S.
    Rosilio, Myriam
    Jung, Heike
    Heitmann, Elke
    Norrbacka, Kirsi
    Federici, Marco Orsini
    Gentilella, Raffaella
    Guerci, Bruno
    Giorgino, Francesco
    Aigner, Ulrich
    Sapin, Helene
    DIABETES THERAPY, 2021, 12 (07) : 1929 - 1946
  • [24] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Luis-Emilio García-Pérez
    Kristina S. Boye
    Myriam Rosilio
    Heike Jung
    Elke Heitmann
    Kirsi Norrbacka
    Marco Orsini Federici
    Raffaella Gentilella
    Bruno Guerci
    Francesco Giorgino
    Ulrich Aigner
    Hélène Sapin
    Diabetes Therapy, 2021, 12 : 1929 - 1946
  • [25] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS
    Garcia-Perez, L. E.
    Sapin, H.
    Norrbacka, K.
    Guerci, B.
    Giorgino, F.
    Aigner, U.
    Federici, Orsini M.
    Gentilella, R.
    Heitmann, E.
    Jung, H.
    Rosilio, M.
    Boye, K.
    VALUE IN HEALTH, 2019, 22 : S593 - S593
  • [26] Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study
    Dang-Tan, Tam
    Kamble, Pravin S.
    Meah, Yunus
    Gamble, Cory
    Ganguly, Rahul
    Horter, Libby
    DIABETES THERAPY, 2020, 11 (01) : 213 - 228
  • [27] Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study
    Tam Dang-Tan
    Pravin S. Kamble
    Yunus Meah
    Cory Gamble
    Rahul Ganguly
    Libby Horter
    Diabetes Therapy, 2020, 11 : 213 - 228
  • [28] REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN THE UNITED STATES
    Pizzicato, Lia
    Nadipelli, Vijay R.
    Samuel, Governor
    Mao, Jianbin
    Lanes, Stephan
    Butler, John
    Pepe, Rebecca S.
    Phatak, Hemant
    El-Kersh, Karim
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1677 - 1677
  • [29] Real-World Outcomes of Initiating Injectable Therapy With Insulin Glargine or Liraglutide Among Patients With Type 2 Diabetes
    Levin, Philip
    Wei, Wenhui
    Vlajnic, Aleksandra
    Pan, Chunshen
    Xie, Lin
    Lin, Jay
    Baser, Onur
    DIABETES, 2012, 61 : A4 - A4
  • [30] ADHERENCE: A REAL WORLD RETROSPECTIVE DATABASE STUDY AMONG TYPE 2 DIABETES PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE
    Maria, M.
    Carlqvist, P.
    Langer, J.
    Bouchard, J.
    VALUE IN HEALTH, 2012, 15 (07) : A503 - A503
12345